Glycoproteomic identification of carbohydrate targeting lung cancer biomarkers

为了开发新的碳水化合物靶向生物标志物用于肺癌的早期检测，对144份血清样本进行了糖蛋白组学分析。我们进一步建立了一种聚糖结构变化的质谱定量方法，称为能量分辨氧离子监测（Erexim）技术，以便对16种已确定的肺癌生物标志物候选物进行大规模验证研究。基于erexim的87份独立血清样本验证实验显示，与正常对照组相比，即使在i期或II期肺腺癌患者中，CD163-Asn105、Asn140和Asn1027上α - 1,6的集中频率也显著上调。Erexim技术于2月18日在美国获得专利（US 8653448）。2014年)，并已应用于各个领域，如生物制剂的化学、制造和控制（CMC）。

To develop novel carbohydrate-targeting biomarkers for early detection of lung cancer, glycoproteomic profiling of 144 serum samples was conducted. We further established a mass spectrometric quantification method for glycan structure alterations, named Energy resolved oxonium ion monitoring (Erexim) technology, in order for large-scaled validation study of 16 identified lung cancer biomarker candidates. The Erexim-based validation experiment using 87 independent serum samples revealed that frequency of alpha-1, 6 fucosylation on CD163-Asn105, Asn140, and Asn1027 was significantly up-regulated in even stage-I or II lung adenocarcinoma patients compared to normal control group. The Erexim technology was patented in US (US 8653448, 18.Feb.2014) and already utilized in various areas, such as chemistry, manufacturing and control (CMC) of biologics.